Globus Medical, Inc. $GMED Stock Holdings Reduced by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 13.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 695,352 shares of the medical device company’s stock after selling 104,930 shares during the quarter. Globus Medical accounts for approximately 1.8% of Anchor Capital Advisors LLC’s portfolio, making the stock its 10th largest holding. Anchor Capital Advisors LLC’s holdings in Globus Medical were worth $60,711,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in GMED. William Blair Investment Management LLC raised its position in Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after acquiring an additional 414,134 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Globus Medical by 49,020.3% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after buying an additional 889,229 shares during the last quarter. Foresight Group Ltd Liability Partnership increased its position in Globus Medical by 160.7% during the third quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock worth $24,142,000 after buying an additional 259,870 shares in the last quarter. Annex Advisory Services LLC acquired a new position in shares of Globus Medical in the fourth quarter worth $20,572,000. Finally, Kingdon Capital Management L.L.C. boosted its stake in shares of Globus Medical by 51.6% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock worth $14,756,000 after purchasing an additional 87,650 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $78.28 on Wednesday. The stock has a 50-day simple moving average of $86.88 and a 200-day simple moving average of $88.39. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The stock has a market capitalization of $10.63 billion, a P/E ratio of 18.20, a PEG ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Wells Fargo & Company decreased their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Finally, Barclays upped their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.